Drug Profile
VX 563
Latest Information Update: 19 Nov 2003
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency; Cystic fibrosis; Huntington's disease; Sickle cell anaemia
Most Recent Events
- 19 Nov 2003 Discontinued - Phase-I for Sickle cell anaemia in USA (unspecified route)
- 19 Nov 2003 Discontinued - Preclinical for Alpha 1-antitrypsin deficiency in USA (unspecified route)
- 19 Nov 2003 Discontinued - Preclinical for Cystic fibrosis in USA (unspecified route)